Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19454550 | 0.92 | GPR119 (0.68) | GPR119GPR183KCNH2CNR2CHRM4 | |
| SCHEMBL12356432 | 0.88 | GPR119 (0.62) | GPR119GPR183KCNH2CNR2CHRM4 | |
| SCHEMBL3261058 | 0.87 | GPR119 (0.60) | GPR119GPR183KCNH2CNR2 | |
| SCHEMBL387876 | 0.86 | GPR119 (0.71) | GPR119GPR183KCNH2CNR2LMNA | |
| SCHEMBL1922450 | 0.85 | GPR119 (0.65) | GPR119GPR183KCNH2CNR2CHRM4 | |
| SCHEMBL19450515 | 0.82 | GPR119 (0.65) | GPR119GPR183KCNH2CNR2 | |
| SCHEMBL1103886 | 0.82 | GPR119 (0.61) | GPR119GPR183KCNH2CHRM4LMNA | |
| SCHEMBL11956913 | 0.82 | GPR119 (0.68) | GPR119GPR183KCNH2CNR2LMNA | |
| SCHEMBL14895589 | 0.82 | GPR119 (0.64) | GPR119GPR183KCNH2CNR2LMNA | |
| SCHEMBL19454993 | 0.82 | GPR119 (0.60) | GPR119GPR183KCNH2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074838-B | Compound having GPR119 agonist activity, method for preparing the same, and pharmaceutical composition comprising the same as an effective ingredient | 东亚ST株式会社 | 2021-03-19 | — | — | CN | disclosed |
| EP-3212640-B1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG A ST CO LTD (KR) | 2019-11-06 | — | — | EP | disclosed |
| EP-3212640-B1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG A ST CO LTD (KR) | 2019-11-06 | — | — | EP | disclosed |
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | 2019-10-01 | — | — | US | disclosed |
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | 2019-10-01 | — | — | US | disclosed |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| EP-3212640-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | Dong-A ST Co., Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016068453-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016068453-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | DONG-A ST CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| EP-2114932-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114935-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114933-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081206-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081208-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081204-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081205-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428055-B2 | Substituted piperidines having GPR119 agonistic activity | GPR119, GPR84, GPR88 | GPR119 1/4885GPR183 38/4885CYP11B2 1658/4885 |
| US-20190092763-A1 | COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMAECUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT | GPR119, FFAR2, GCGR | GPR119 1/4885GPR183 30/4885CYP11B2 1197/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885GPR183 20/4885CYP11B2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.